

SUPPLEMENT APPROVAL April 18, 2019

Alba Bioscience Limited Attention: Mr. Robert Dorris 21 Ellens Glen Road Edinburgh EH17 7QT United Kingdom

Dear Mr. Dorris:

We have approved your requests submitted March 15, 2018, received March 16, 2018, to supplement your Biologics License Applications (BLA) submitted under section 351(a) of the Public Health Service Act to manufacture the following Blood Grouping Reagents from antibody concentrates supplied by (b) (4) under a shared manufacturing arrangement.:

STN Name of Biological Products

BL 125567/3	Blood Grouping Reagent, Anti-Fy ^a (Monoclonal) (IgG)
BL 125568/3	Blood Grouping Reagent, Anti-Jk ^a (Monoclonal)
BL 125569/4	Blood Grouping Reagent, Anti-Jk ^b (Monoclonal)
BL 125570/3	Blood Grouping Reagent, Anti-S (Monoclonal)(IgG)
BL 125571/3	Blood Grouping Reagent, Anti-s (Monoclonal)(IgG)
BL 125572/3	Blood Grouping Reagent, Anti-K (Monoclonal)
BL 125573/3	Blood Grouping Reagent, Anti-P1 (Murine Monoclonal)

LABELING

We hereby approve the draft package insert labeling submitted under amendment 4, dated February 15, 2019. This is a reminder that as of September 24, 2014, medical devices that are licensed under the PHS Act are subject to certain provisions of the final Unique Device Identifier (UDI) rule. These provisions include the requirement to provide a UDI on the device label and packages (21 CFR 801.20), format dates on the device label in accordance with 21 CFR 801.18, and submit data to the Global Unique Device Identification Database (GUDID) (21 CFR 830 Subpart E). Additionally, please identify each device identifier implemented for the subject device, and the device identifiers that have been discontinued for the subject device as a labeling change in an annual report consistent with 21 CFR 601.12(f)(3). For more information on these requirements, please see the UDI website at http://www.fda.gov/udi.

Please submit all final printed labeling as PDF electronic copy (eCopy) at the time of use and include implementation information on Form FDA 356h as appropriate.

Two draft copies of the proposed introductory advertising or promotional labeling may be voluntarily submitted for advisory comment with a completed Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration Center for Biologics Evaluation and Research Document Control Center 10903 New Hampshire Ave. WO71–G112 Silver Spring, MD 20993-0002

Please submit an amendment to all pending supplemental applications for these BLAs that include revised labeling incorporating a revised content of labeling that includes this change.

We will include information contained in the above-referenced supplements in your BLA files.

Sincerely,

Orieji Illoh, MD Director Division of Blood Components and Devices Office of Blood Research and Review Center for Biologics Evaluation and Research